Dementia Patient Articles & Analysis
6 news found
Ariana Pharma, the leading Al-driven precision medicine company, has announced the first comprehensive blarcamesine pathway analysis impact using extensive data from the ANAVEX®2-73-PDD-001 Parkinson’s Disease Dementia (PDD) clinical study. Initial results were presented by Ariana Pharma at the Alzheimer’s Association International Conference (AAIC 2022) in San Diego, in ...
About TRANQUILITY II and III Initiated in December of 2021, TRANQUILITY II and III are pivotal Phase 3 trials evaluating BXCL501 for the acute treatment of agitation in patients with Alzheimer’s disease. The trials expand the evaluation of patients who experience agitation across diverse medical settings and across the range of dementia ...
Moreover, it can assist with treatment optimisation through symptom tracking, which for many patients can delay deterioration to the stage where interventions and long-term care costs increase. ...
In Japan, clinical MRI scanners are available for the diagnosis and evaluation of dementia. Brain imaging by MRI is available for patients with dementia and the prodromal stages using standard health insurance. However, regular MRI images are of limited use in the differential diagnosis of dementia or estimating its severity as ...
ABOUT WANDERING IN DEMENTIA PATIENTS Dementia is the leading cause of dependency and disability amongst older adults. ...
Alzheimer’s awareness month, Optina Diagnostics and Wagner Macula Retina Center will Collaborate to Conduct a Clinical Study and Develop a Unique in-community Patient access Program Aimed to Identify the Causes of Memory Loss through Eye Diagnostics, November 6th 2019 Optina Diagnostics Optina Diagnostics, a world leading company in retinal imaging and artificial ...